Apollomics (APLM) Payables (2023)
Apollomics (APLM) reported Payables of $4.2 million for Q4 2023, up 347.31% quarter-over-quarter from $947000.0 in Q2 2023.
Apollomics (APLM) Payables (2023) Analysis & Trends
Apollomics (APLM) has 1 years of Payables data on file, last reported at $4.2 million in Q4 2023.
- Payables for Q4 2023 came in at $4.2 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2023 was $4.2 million (changed N/A YoY), and the FY2023 annual result was $4.2 million, changed N/A from the prior year.
- Payables climbed to $4.2 million in Q4 2023 per APLM's latest filing, from $947000.0 in the prior quarter.
- Over five years, Payables peaked at $4.2 million in Q4 2023 and troughed at $947000.0 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | 1.05 Mn |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | 300,549.00 |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 83.00 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | 8.69 Mn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 489.30 Mn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | 34.55 Mn |
| 10 | Apollomics | 294.00 Mn | 294.00 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 4.24 Mn |
| Jun 30, 2023 | 947,000.00 |